{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:14:11Z","timestamp":1777158851232,"version":"3.51.4"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Clinical guidelines recommend continuation of sodium\u2010glucose cotransporter\u20102 inhibitor (SGLT2i) treatment when renal function deteriorates among patients with type 2 diabetes. However, the recommendation is not currently supported by research specifically designed to compare continuation versus discontinuation of SGLT2is for patients who have received the treatment for a while before experiencing renal function deterioration. Using linked Taiwanese databases with claims and clinical data and a target trial emulation framework, we conducted a nationwide cohort study to investigate the association between SGLT2i continuation and major cardiorenal outcomes after renal function declined. We identified patients with type 2 diabetes who received SGLT2is during 2016\u20132020, who either continued or discontinued SGLT2is within 180\u2009days after their eGFR declined below 45\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>. The study outcomes were myocardial infarction, stroke, heart failure, acute kidney injury, and all\u2010cause mortality. We estimated the on\u2010treatment and intention\u2010to\u2010treat hazard ratios (HRs) and 95% confidence intervals (CIs) comparing SGLT2i continuation versus SGLT2i discontinuation, adjusting for baseline and time\u2010varying covariates using inverse probability weighting. Among 11,467 eligible patients, the on\u2010treatment HR associated with SGLT2i continuation was 0.83 (95% CI, 0.59\u20131.18) for myocardial infarction, 0.74 (0.56\u20130.95) for stroke, 0.58 (0.49\u20130.69) for heart failure, 0.53 (0.45\u20130.63) for acute kidney injury, and 0.51 (0.42\u20130.61) for all\u2010cause mortality. The results did not change meaningfully in the intention\u2010to\u2010treat analysis or within pre\u2010specified patient subgroups, including patients with eGFR below 30\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> or prior acute kidney injury. Our findings provide scientific evidence to support continuing SGLT2i use when renal function declines during the SGLT2i treatment course.<\/jats:p>","DOI":"10.1111\/cts.70319","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:49:45Z","timestamp":1754988585000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Continuation Versus Discontinuation of Sodium\u2010Glucose Cotransporter\u20102 Inhibitors and Cardiorenal Outcomes Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study With a Target Trial Emulation Framework"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-4113","authenticated-orcid":false,"given":"Yaa\u2010Hui","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, College of Pharmaceutical Sciences National Yang Ming Chiao Tung University  Taipei Taiwan"},{"name":"Institute of Public Health, School of Medicine National Yang Ming Chiao Tung University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-6177","authenticated-orcid":false,"given":"Chia\u2010Hsuin","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"},{"name":"Department of Medicine, College of Medicine National Taiwan University  Taipei Taiwan"},{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health National Taiwan University  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-6434","authenticated-orcid":false,"given":"Li\u2010Chiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-0810","authenticated-orcid":false,"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12312"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00519-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01476-x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_11_10_1","unstructured":"National Health Insurance Administration \u201c2022\u20132023 National Health Insurance Annual Report \u201dhttps:\/\/www.nhi.gov.tw\/ch\/cp\u20103153\u2010f49da\u20102456\u20101.html."},{"key":"e_1_2_11_11_1","unstructured":"National Health Insurance Administration \u201cNational Health Insurance Statistics\u20102001 \u201dhttps:\/\/www.nhi.gov.tw\/ch\/cp\u20104671\u2010befc5\u20103022\u20101.html."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S286572"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2018062"},{"key":"e_1_2_11_14_1","unstructured":"National Health Insurance Administration \u201cDiabetes Pay\u2010For\u2010Performance Program \u201dhttps:\/\/www.nhi.gov.tw\/ch\/np\u20102825\u20101.html."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1230"},{"key":"e_1_2_11_18_1","unstructured":"U.S. Food and Drug Administration (FDA) \u201cFDA Drug Safety Communication: FDA Strengthens Kidney Warnings for Diabetes Medicines Canagliflozin (Invokana Invokamet) and Dapagliflozin (Farxiga Xigduo Xr) \u201dhttps:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010fda\u2010strengthens\u2010kidney\u2010warnings\u2010diabetes\u2010medicines\u2010canagliflozin."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20140076"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14151"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2013.09.009"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S273853"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S288518"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.2.197"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4690"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","DOI":"10.1177\/2054358119827525","article-title":"A Validation Study of Administrative Health Care Data to Detect Acute Kidney Injury in the Pediatric Intensive Care Unit","volume":"6","author":"D'Arienzo D.","year":"2019","journal-title":"Canadian Journal of Kidney Health and Disease"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40697-016-0108-7"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.012"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000729"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100183"},{"key":"e_1_2_11_32_1","first-page":"721","article-title":"Validating the Adapted Diabetes Complications Severity Index in Claims Data","volume":"18","author":"Chang H. Y.","year":"2012","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.02.018"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00012"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-022-00856-7"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0447-z"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.10.004"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwad090"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13531"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110621"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110200"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42989-z"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191283"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0201"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02480221"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T17:20:31Z","timestamp":1755969631000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/cts.70319"],"URL":"https:\/\/doi.org\/10.1111\/cts.70319","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70319"}}